Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of death related to liver diseases worldwide. Despite this, there is no specific treatment approved for the disease till now, which could be due to the poor understanding of the pathophysiology of this disease. In the past few decades, several scientists have speculated the root cause of NAFLD to be dysbalance in the gut microbiome resulting in a susceptibility to the inflammatory cascade in the liver. Herein, we hypothesize to fabricate a novel formulation containing prebiotic with probiotics which thereby would help in maintaining the gut homeostasis, and be used for the treatment of NAFLD. The proposed novel formulation would contain a Bifidobacterium sp. with Faecalibacterium prausnitzii in the presence of a dietary fibre having hepatoprotective activity. These two strains of probiotics would help in increasing the concentration of butyrate in the gut which in turn would inhibit intestinal inflammation and maintain gut integrity. The dietary fibre would serve a dual mechanism; firstly, it would act as a prebiotic helping in the proliferation of administered probiotics, and secondly, it would protect the liver via its own hepatoprotective action. This combinatorial approach would pave a new therapeutic avenue for the treatment of NAFLD.
Keywords: NAFLD, gut liver axis, microbiota, microbiome, dysbiosis, Bifidobacterium, Faecalibacterium.
Current Pharmaceutical Design
Title:Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Volume: 27 Issue: 46
Author(s): Tanya Ralli*, Yub Raj Neupane, Zoya Saifi and Kanchan Kohli*
Affiliation:
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062,India
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062,India
Keywords: NAFLD, gut liver axis, microbiota, microbiome, dysbiosis, Bifidobacterium, Faecalibacterium.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of death related to liver diseases worldwide. Despite this, there is no specific treatment approved for the disease till now, which could be due to the poor understanding of the pathophysiology of this disease. In the past few decades, several scientists have speculated the root cause of NAFLD to be dysbalance in the gut microbiome resulting in a susceptibility to the inflammatory cascade in the liver. Herein, we hypothesize to fabricate a novel formulation containing prebiotic with probiotics which thereby would help in maintaining the gut homeostasis, and be used for the treatment of NAFLD. The proposed novel formulation would contain a Bifidobacterium sp. with Faecalibacterium prausnitzii in the presence of a dietary fibre having hepatoprotective activity. These two strains of probiotics would help in increasing the concentration of butyrate in the gut which in turn would inhibit intestinal inflammation and maintain gut integrity. The dietary fibre would serve a dual mechanism; firstly, it would act as a prebiotic helping in the proliferation of administered probiotics, and secondly, it would protect the liver via its own hepatoprotective action. This combinatorial approach would pave a new therapeutic avenue for the treatment of NAFLD.
Export Options
About this article
Cite this article as:
Ralli Tanya*, Neupane Raj Yub, Saifi Zoya and Kohli Kanchan*, Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease, Current Pharmaceutical Design 2021; 27 (46) . https://dx.doi.org/10.2174/1389201022666210625141526
DOI https://dx.doi.org/10.2174/1389201022666210625141526 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Analysis of Anticancer Drugs and their Metabolites by Mass Spectrometry
Current Drug Metabolism Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Prospects of Developing Medicinal Therapeutic Strategies and Pharmaceutical Design for Effective Gluten Intolerance Treatment
Current Pharmaceutical Design Recent Developments on the Synthesis of Biologically Significant bis/tris(indolyl)methanes under Various Reaction Conditions: A Review
Current Organic Chemistry Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Radiolabeled Glucose Derivatives for Tumor Imaging Using SPECT and PET
Current Medicinal Chemistry The Effect on the Intestine of Some Fungal Toxins: The Trichothecenes
Current Immunology Reviews (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design